These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15133754)

  • 1. Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes.
    Go EH; Kyriakidou-Himonas M; Berelowitz M
    Diabetes Metab Res Rev; 2004; 20(3):225-31. PubMed ID: 15133754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2003 May; 52(5):565-72. PubMed ID: 12759885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
    Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA
    Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.
    Mooradian AD; Albert SG; Bernbaum M; Plummer S
    Diabetes Care; 1996 Aug; 19(8):883-4. PubMed ID: 8842609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
    Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
    Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2004 Apr; 53(4):414-22. PubMed ID: 15045685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.
    Cefalu WT; Schneider DJ; Carlson HE; Migdal P; Gan Lim L; Izon MP; Kapoor A; Bell-Farrow A; Terry JG; Sobel BE
    Diabetes Care; 2002 Dec; 25(12):2123-8. PubMed ID: 12453948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.
    Feinglos M; Dailey G; Cefalu W; Osei K; Tayek J; Canovatchel W; Chaiken R; Kourides I
    Diabetes Res Clin Pract; 2005 May; 68(2):167-75. PubMed ID: 15860246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes.
    Hussain SA
    J Med Food; 2007 Sep; 10(3):543-7. PubMed ID: 17887949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.
    Foster RH; Plosker GL
    Pharmacoeconomics; 2000 Sep; 18(3):289-306. PubMed ID: 11147395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
    Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months.
    Birkeland KI; Furuseth K; Melander A; Mowinckel P; Vaaler S
    Diabetes Care; 1994 Jan; 17(1):45-9. PubMed ID: 8112188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
    Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
    Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
    Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
    Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.
    Shank ML; Del Prato S; DeFronzo RA
    Diabetes; 1995 Feb; 44(2):165-72. PubMed ID: 7859936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.